SXTC
China SXT Pharmaceuticals, Inc.
There isn't enough reported data to score SXTC yet.
SXTC Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Strong |
SXTC's balance sheet is currently strong, but its profitability is weak. There isn't enough data to rate its revenue and cash flow.
SXTC PE Valuation
SXTC has no meaningful PE right now: it lost money over the past year.
SXTC Forward outlook
There aren't enough analyst estimates for SXTC to show an outlook.
SXTC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q1 2019 | $1,440,000,000.00 | +6592401% |
SXTC has swung to a loss: it lost $258,864,000.00 per share over the past year, after a profit the year before.
SXTC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $511.5K | -44% |
| Q3 2025 | $626.6K | -24% |
| Q1 2025 | $911.4K | -7.8% |
| Q3 2024 | $829.5K | -12% |
| Q1 2024 | $988.9K | +30% |
| Q3 2023 | $939.6K | -22% |
| Q1 2023 | $763.4K | -52% |
| Q3 2022 | $1.2M | +18% |
SXTC's revenue has slid since its 2019 peak: $511,482 last quarter, down 48% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2026 | -153% | -844 points |
| Q3 2025 | -1012% | -17 points |
| Q1 2025 | -224% | +360 points |
| Q3 2024 | -77% | +18 points |
| Q1 2024 | 691% | +837 points |
| Q3 2023 | -995% | -714 points |
| Q1 2023 | -584% | -217 points |
| Q3 2022 | -95% | -125 points |
SXTC's operating margin was −153% last quarter, down 844 points from the same quarter a year ago.
SXTC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2022 | -$569.2K | -$235.8K |
| Q1 2022 | $540.8K | +$1.6M |
| Q3 2021 | -$333.5K | +$5K |
| Q1 2021 | -$1.1M | -136% |
| Q3 2020 | -$338.4K | +$1.8M |
| Q1 2020 | $3M | +$3.2M |
| Q1 2019 | -$296.6K | -126% |
| Q1 2018 | $1.2M | +2543% |
SXTC has burned cash in six of the last eight quarters: −$1M over the past year, against $168,336 the year before.
SXTC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -85% | -88 shares |
| Quarter | Spent |
|---|---|
| Q1 2018 | — |
| Q4 2017 | — |
| Q3 2017 | — |
| Q2 2017 | — |
| Q1 2017 | — |
SXTC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2024 | -2.8x | Net Cash |
| Q3 2020 | -24.2x | Net Cash |
| Q1 2019 | -4.7x | Net Cash |
| Q1 2018 | -0.1x | Net Cash |
| Q4 2017 | 0.1x | Very low |
SXTC has more cash than debt.
SXTC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 26.3 | Oversold |
| Stochastic | 0.0 | Oversold |
SXTC's weekly RSI is 26 (oversold) and its Stochastic is 0 (oversold).
SXTC PE vs Healthcare Sector
| Metric | SXTC | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
SXTC has no meaningful PE right now: it lost money over the past year.
SXTC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $66.5 | 96% below |
| 20 week MA | $3,168.2 | 100% below |
| 50 week MA | $201,104.1 | 100% below |
| 100 week MA | $1,416,712.0 | 100% below |
| 200 week MA | $16,515,528.3 | 100% below |
SXTC is in a downtrend: it's below all five of its weekly moving averages, and 100% below its 200-week average.
SXTC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $14,687,808,000.0 | $6,504,960,000.0 | -56% |
| 2021 | $6,504,960,000.0 | $2,753,856,000.0 | -58% |
| 2022 | $2,753,856,000.0 | $124,800,000.0 | -95% |
| 2023 | $124,800,000.0 | $38,112,000.0 | -69% |
| 2024 | $38,112,000.0 | $4,012,800.0 | -89% |
| 2025 | $4,012,800.0 | $1,812,000.0 | -55% |
| 2026 YTD | $1,812,000.0 | $2.73 | -100% |
SXTC has finished every year since 2020 lower, and it's down 100% so far in 2026.